324 related articles for article (PubMed ID: 32421502)
1. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications.
Long B; Brém E; Koyfman A
West J Emerg Med; 2020 Apr; 21(3):566-580. PubMed ID: 32421502
[TBL] [Abstract][Full Text] [Related]
2. Cytokine release syndrome: grading, modeling, and new therapy.
Liu D; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):121. PubMed ID: 30249264
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
Fishman JA; Hogan JI; Maus MV
Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
[TBL] [Abstract][Full Text] [Related]
4. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
7. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
8. New Immunotherapies in Oncology Treatment and Their Side Effect Profiles.
Sriratana P; Norton J
J Am Board Fam Med; 2018; 31(4):620-627. PubMed ID: 29986988
[TBL] [Abstract][Full Text] [Related]
9. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune complications of cancer immunotherapy.
Dhodapkar KM
Curr Opin Immunol; 2019 Dec; 61():54-59. PubMed ID: 31557690
[TBL] [Abstract][Full Text] [Related]
11. [Cancer immunotherapy].
Kjeldsen JW; Donia M; Svane IM
Ugeskr Laeger; 2018 May; 180(21):. PubMed ID: 29804567
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular toxicity of immune therapies for cancer.
Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.
Davda J; Declerck P; Hu-Lieskovan S; Hickling TP; Jacobs IA; Chou J; Salek-Ardakani S; Kraynov E
J Immunother Cancer; 2019 Apr; 7(1):105. PubMed ID: 30992085
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
Peyrony O; Tieghem Y; Franchitti J; Ellouze S; Morra I; Madelaine-Chambrin I; Flicoteaux R; Baroudjian B; Azoulay E; Chevret S; Fontaine JP
Emerg Med J; 2019 May; 36(5):306-309. PubMed ID: 30910911
[TBL] [Abstract][Full Text] [Related]
15. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
16. Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice.
Berzero G; Picca A; Psimaras D
Curr Opin Oncol; 2020 Nov; 32(6):603-612. PubMed ID: 32852312
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C; Desbaillets N; Hottinger AF
Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
19. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
20. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sandigursky S; Mor A
Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
